The global fast disintegrating tablets market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The key factor that drives the market growth and rapid adoption of these tablets among the global population includes the improved patient compliance due to these tablets when compared to the conventional tablets and capsules. It is majorly due to the comparatively better taste of these orally disintegrating tablets than the traditional ones. 

Another pivotal factor contributing substantially to the market growth comprises the ability of fast disintegrating tablets to bypass first-pass metabolism. This indicates that these tablets are effective in addressing the complexities related to drug concentration; thus it also sustains the bioavailability of self-administered drugs. This maintained bioavailability offered by such tablets specifically for protein and peptide-based therapeutics is a promising factor for market growth during the forecast period.

Some key players operating in the market include Teva, Merck, Mylan, Pfizer, Johnson and Johnson. These players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.

For instance, in December 2018, Biohaven Pharmaceutical Holding Co. Ltd. announced positive top-line results from a randomized, controlled Phase 3 clinical trial evaluating the efficacy and safety of its Zydis, which is an orally dissolving tablet / fast disintegrating formulation of Rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist for the acute treatment of migraines. Such successful clinical trials are anticipated to further provide a boost to the global market growth in the future years.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape:  Teva, Merck, Mylan, Pfizer, Johnson and Johnson among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Fast Disintegrating Tablets Market Report Segmentation

By Type 

• Anti-Psychotics Drug

• Anti-Epileptics Drug

• Other

By Application 

• CNS Diseases

• Gastrointestinal Diseases

• CVS Diseases

• Other

Global Fast Disintegrating Tablets Market by Region